Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Immediate pushing Clear all
Completed Phase 2 Interventional Results available

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

NCT04357730
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
Interventions
Alteplase 50 MG [Activase]
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 24, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

NCT01207765
View directory record Official record
Conditions
Multiple Myeloma
Interventions
indium-111-ibritumomab tiuxetan, 90Y Zevalin
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 24, 2026, 5:45 AM EDT
Not yet recruiting Not applicable Interventional

Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial

NCT07606313
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Cancer, Functional Limitation
Interventions
Functional Resistance Training, Stretching, Delayed Functional Resistance Training
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 24, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

NCT01795586
View directory record Official record
Conditions
Breast Cancer
Interventions
Eribulin, Carboplatin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 24, 2026, 5:45 AM EDT
Terminated Phase 1 Interventional

A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

NCT01258634
View directory record Official record
Conditions
Osteosarcoma, Lung Metastases
Interventions
Dexrazoxane, Doxorubicin, Cisplatin, G-CSF, PEG-filgrastim, Etoposide, Ifosfamide, Mesna, Leucovorin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
2 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 24, 2026, 5:45 AM EDT
Terminated Phase 4 Interventional Results available

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa

NCT00626574
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Epoetin alfa, Saline
Drug
Lead sponsor
University of South Florida
Other
Eligibility
30 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 24, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Self-Administered Maneuver to Relieve Symptoms Suggestive of Benign Prostatic Hyperplasia

NCT01387893
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
the Digital Repetitive Infrapubic Pressure maneuver
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
45 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 24, 2026, 5:45 AM EDT
Withdrawn No phase listed Observational

High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

NCT01973517
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Feraheme, Gadolinium-based contrast
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 24, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization

NCT04080167
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
InCharge Health mobile application, HU Toolbox mobile application
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
15 Years to 45 Years
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
7
States / cities
Augusta, Georgia • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 24, 2026, 5:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Ambulatory Cancer Care Electronic Symptom Self-Reporting for Surgical Patients

NCT03178045
View directory record Official record
Conditions
Patient Reported Outcomes
Interventions
Team Monitoring, Enhanced Feedback
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
2,793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 24, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Public Messaging to Increase Treatment Seeking for Veterans at Risk for Suicide

NCT04784663
View directory record Official record
Conditions
Mental Health, Suicide
Interventions
Messaging, Wait list control
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Canandaigua, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 24, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

NCT01160484
View directory record Official record
Conditions
Multiple Myeloma
Interventions
DVD-R
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Bakersfield, California • Fresno, California • Loma Linda, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 24, 2026, 5:45 AM EDT
Terminated No phase listed Observational

Breath Metabolomics in the Laboring Parturient

NCT04564196
View directory record Official record
Conditions
Labor Onset and Length Abnormalities
Interventions
Breath Sample
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 24, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation

NCT02807623
View directory record Official record
Conditions
Immune System and Related Disorders
Interventions
Ibuprofen, Compound Exercise of Push-ups, oral placebo
Drug · Behavioral
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 24, 2026, 5:45 AM EDT
Completed Phase 4 Interventional Results available

Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy

NCT02213900
View directory record Official record
Conditions
Delirium, Cognitive Impairment, Post-traumatic Stress Disorder, Depression, Anxiety
Interventions
Haloperidol, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 24, 2026, 5:45 AM EDT
Not listed Not applicable Interventional

Passive Descent in Obese Nulliparous Gravidae

NCT02080429
View directory record Official record
Conditions
Management of the Second Stage of Labor in Obese Nulliparous Women by Either Passive Descent or Immediate Pushing.
Interventions
Passive Descent, Pushing
Procedure
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
Female only
Enrollment
540 participants
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 24, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 24, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial

NCT05378113
View directory record Official record
Conditions
Injection Site Irritation
Interventions
Ondansetron, Lidocaine
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 24, 2026, 5:45 AM EDT
Not yet recruiting Not applicable Interventional

Strong as a Mother

NCT07867275
View directory record Official record
Conditions
Postpartum Physical Fitness and Functional Performance
Interventions
Supervised Postpartum Functional Strength Training and Aerobic Conditioning
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 5:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 24, 2026, 5:45 AM EDT
Recruiting Not applicable Interventional

Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individuals With Diabetic Peripheral Neuropathy

NCT06591780
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Diabetes Mellitus
Interventions
Clinical Evaluation, Plantar Pressure Biofeedback Gait Training, Propulsion Biofeedback Gait Training
Other
Lead sponsor
Florida Institute for Human and Machine Cognition
Other
Eligibility
45 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 24, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Opioid Approach Bias Modification

NCT04436926
View directory record Official record
Conditions
Opioid Use, Chronic Pain
Interventions
opioid approach bias modification, sham training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 24, 2026, 5:45 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Optimizing Management of the 2nd Stage of Labor: Multicenter Randomized Trial

NCT02137200
View directory record Official record
Conditions
Pregnancy
Interventions
Immediate pushing, Delayed pushing
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
2,414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • St Louis, Missouri • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 24, 2026, 5:45 AM EDT
Terminated Phase 1 Interventional Results available

Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

NCT00928200
View directory record Official record
Conditions
Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase
Interventions
Erwinase, Vincristine, Dexamethasone, Doxorubicin, Cytarabine, Methotrexate, Triple Intrathecal Therapy, Dexrazoxane
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 24, 2026, 5:45 AM EDT